Precipio

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Precipio (PRPO) reports revenue growth and aims for profitability

Precipio's Q2 performance reflects positive momentum in revenue growth and operational improvements. While challenges like achieving profitability and FDA approval exist, the company's focus on building relationships and scaling up presents opportunities for future growth. Overall, Precipio is well-positioned to achieve its goals and enhance investor relations post-profitability.

Precipio (PRPO) achieves record diagnoses, nears breakeven in Q3 2024

Precipio's Q3 2024 earnings call highlights strong revenue growth, progress towards breakeven, and improved financial stability. While facing challenges in investor relations, the company's focus on education and visibility initiatives shows a proactive approach to addressing concerns. Leveraging key customer relationships and sustainable growth strategies offer promising opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prominent Laboratories in US and Europe will begin testing the media Prominent Laboratories in US and Europe will begin testing the media

Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™

Panel of clinically critical genes can yield same-day results outperforming major competitors Panel of clinically critical genes can yield same-day results outperforming major competitors

Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy

Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans

Partnership is expected to accelerate product introduction to most major labs worldwide Partnership is expected to accelerate product introduction to most major labs worldwide

Precipio & ADS Biotec Sign Global Distribution Agreement for IV-Cell™

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2020 Results - Earnings Call Transcript

Conference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST Conference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST

Precipio Announces Q2-2020 Corporate Update Call For Shareholders

Test initially offered to Precipio’s customer base, then expanding distribution reach Test initially offered to Precipio’s customer base, then expanding distribution reach

Precipio Launches Covid-19 Antibody Test in its CLIA laboratory

Precipio (NASDAQ: PRPO) shares are trading higher on Thursday. The company announced it entered into an agreement with ADS Biotec to distribute its FDA-authorized COVID-19 serology antibody tests that recently received Emergency Use Authorization.

Why Precipio's Stock Is Rocketing Higher Today

Test received FDA EUA; commercialization begins Test received FDA EUA; commercialization begins

Precipio Announces Commercial Launch of COVID-19 Antibody Test

NEW HAVEN, Conn., July  22, 2020  (GLOBE NEWSWIRE) -- Specialty diagnostics company  Precipio, Inc.  ( NASDAQ: PRPO ), announced its preliminary unaudited revenues for its pathology services increased from $0.8M in Q1’20, to an estimated (unaudited) $1.3M in Q2’20, an increase of approximately 50% quarter-over-quarter. Final numbers are subject to the completion of the company’s quarterly review and will be released in the company’s upcoming 10-Q filing.

Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1’20

NEW HAVEN, Conn., July  01, 2020  (GLOBE NEWSWIRE) -- Specialty diagnostics company  Precipio, Inc.  ( NASDAQ: PRPO ), announced that it has regained compliance with the Nasdaq listing requirements. On June 29, 2020, the Company received a letter from Nasdaq stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed. 

Precipio Regains Listing Compliance with NASDAQ Minimum Bid Requirement

Newly Created Reagent Rental Program Continues to Gain HemeScreen Adopters Newly Created Reagent Rental Program Continues to Gain HemeScreen Adopters

Precipio Adds Another HemeScreen™ Customer

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q1 2020 Results - Earnings Call Transcript

Precipio Pathology Sales Performance Metrics Demonstrate Growth in Customer Acquisition, Retention, and Total Case Volume Precipio Pathology Sales Performance Metrics Demonstrate Growth in Customer Acquisition, Retention, and Total Case Volume

Q1-2020 Net Revenues increase 77% over Q4-2019 to $1.2M

Conference Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST Conference Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST

Precipio Announces Q1-2020 Corporate Update Call For Shareholders

Oncology Practices Improve Patient care and Increase Revenue & Profit Oncology Practices Improve Patient care and Increase Revenue & Profit

Precipio Launches New HemeScreen™ Reagent Rental Program

Letter to the Shareholders from the CEO Letter to the Shareholders from the CEO

Company Update During the COVID-19 Era

Customer base and sales team transition to Precipio, Doubling Revenues Customer base and sales team transition to Precipio, Doubling Revenues

Precipio Completes the Transaction with Poplar Healthcare’s Oncometrix Hematopathology Division

Groundbreaking clinical and economic impact to be generated

Precipio achieves impressive initial results of Artificial Intelligence Decision-Support Tool

NEW HAVEN, Conn., Feb.  18, 2020  (GLOBE NEWSWIRE) -- Specialty diagnostics company  Precipio, Inc.  ( NASDAQ: PRPO ), announced today that it is in advanced discussions with  Poplar Healthcare  to establish a strategic partnership that includes, among other transactions, the acquisition of the customer base of Poplar’s Hematopathology division,  OncoMetrix .

Precipio in advanced discussions with Poplar Healthcare towards a multi-faceted strategic partnership

NEW HAVEN, Conn., Jan.  28, 2020  (GLOBE NEWSWIRE) -- The management team of Specialty diagnostics company  Precipio, Inc.  ( NASDAQ: PRPO ), would like to provide an explanation on the recent Amendment to the S-1 that was filed yesterday, on January 27, 2020.

Precipio Provides Clarification To Amendment No.1 to Form S-1 Filing

NEW HAVEN, Conn., Jan.  15, 2020  (GLOBE NEWSWIRE) -- The management team of Specialty diagnostics company  Precipio, Inc.  ( NASDAQ: PRPO ), would like to provide several clarification points related to the recent S-1 that was filed yesterday, on January 14, 2020:

Precipio Provides Clarification To Recent S-1 Filing

NEW HAVEN, Conn., Jan.  13, 2020  (GLOBE NEWSWIRE) -- Specialty diagnostics company  Precipio, Inc.  ( NASDAQ: PRPO ), announced that on Monday, January 20th at 5pm it will conduct a shareholder update call with regard to several strategic initiatives for 2020 as well as the current status of IV-cell and Hemescreen deployment and the diversification of our business model into the products sector.

Precipio announces shareholder update call to kick off 2020

Precipio's (PRPO) CEO Ilan Danieli on Q3 2019 Results - Earnings Call Transcript

Following completion of a successful validation testing, laboratory set to launch assay Following completion of a successful validation testing, laboratory set to launch assay

News for Precipio Stock (PRPO)